Public COA audit
Retatrutide
Audited July 29, 2026
Several fields check out, but we found issues worth reviewing before you rely on this document.
- Legitimacy
- 72
- Confidence
- 83%
- Panels
- 2/7
- Purity (printed)
- 99.8%
Document details
Fields extracted from the certificate — not order or payment data.
- Batch / lot
- EMY3DEX
- Identity method
- FTIR (USP <197A>)
- Sample date
- 2026-01-26
- Issue date
- 2026-01-28
7-panel checklist
Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.
2 of 7 present · 2 passed · 0 failed · 0 reported · 5 missing
Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.
Identity
Tested · passed · core
Compound identity confirmed (e.g. HPLC, mass spec).
FTIR sample spectrum confirms the presence of Retatrutide with addition of excipient(s)/fillers such as mannitol
Purity
Tested · passed · core
Reported purity percentage for the analyte.
99.8%
Heavy metals
Not on this COA
Lead, arsenic, cadmium, mercury, or similar limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Microbial
Not on this COA
Bioburden / microbial limits testing.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Endotoxin
Not on this COA · core
LAL or chromogenic endotoxin assay.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Sterility
Not on this COA
Sterility testing where applicable.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Residual solvent / water
Not on this COA
Residual solvents or water content limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
How to read this
Had data · good
Panel present with a pass (or clear acceptance).
Had data · bad
Panel present with a fail — a concrete quality signal.
Had data · unclear
Value reported without an explicit pass/fail mark.
Missing
Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.
Findings
Evidence-linked observations from this audit.
High HPLC purity
99.8% purity by HPLC is excellent and typical for research-grade peptides
FTIR confirmation
FTIR spectrum confirms Retatrutide identity with mannitol excipient detected
Potency below specification
HPLC potency assay shows 8.9 mg (88.8%) vs. specification of 95-105% of 10 mg labeled content. This is a failure of the potency specification.
Batch number present
Lot number EMY3DEX clearly documented
Dates documented
Sample tested 2026-01-26, report issued 2026-01-28 (both valid and reasonable)
Dual branding
Document shows both BTLabs branding and Finnrick Testing Certificate header with different verification URLs (btlabtesting.com vs finnrick.com/verify). This dual branding pattern is unusual and may indicate a reseller/intermediary relationship.
Limited testing scope
Testing purpose explicitly states it does NOT provide information on particulate matter, microbial contamination, or endotoxins. No heavy metals, sterility, or residual solvent testing performed.
Professional presentation
Document includes FTIR spectrum, HPLC chromatogram, digital signatures, and proper USP method references
PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.